Search Results - Yingdan Cao

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Cover Image

    The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China by Rui Meng, Yingdan Cao, Ting Zhou, Hongfei Hu, Yijin Qiu

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  2. 2
    Cover Image

    Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma by Ting Zhou, Xintian Wang, Yingdan Cao, Lan Yang, Zijing Wang, Aixia Ma, Hongchao Li

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: